Literature DB >> 12531355

Priming characteristics of peptide mimotopes of carbohydrate antigens.

Behjatolah Monzavi-Karbassi1, Shahram Shamloo, Matthew Kieber-Emmons, Fariba Jousheghany, Ping Luo, Kaity Y Lin, Gina Cunto-Amesty, David B Weiner, Thomas Kieber-Emmons.   

Abstract

Immunization with peptide mimetics of carbohydrate antigens can induce functional carbohydrate-reactive antibodies. Here, we examine the immune characteristics of alternative approaches in prime and boost strategies using glycosylated HIV-1 envelope protein and model tumor associated carbohydrate antigens. Our results indicate that peptide mimotopes either in a DNA or carrier-conjugated format can induce comparable levels of IgM and IgG. Carbohydrate boosting of peptide-primed animals does not affect end-point titer, however, boosting mediates a stable long lasting carbohydrate reactive IgM response, not achievable by carbohydrate immunization alone. Boosting with carbohydrate in animals primed with DNA- or peptide-conjugate, facilitates the induction of detectable IgG with a dominant IgG2a isotype. Immunization with HIV-1 envelope glycoprotein of peptide-primed animals induces different IgG isotype profiles with a dominant IgG1 antibody. We observed that HIV-1 envelope glycoprotein immunization of peptide primed mice induces a cross-reactive cellular response, as detected by cytokine secretion, which lends to IFN-gamma production upon splenocyte stimulation and CTL activity against recombinant vaccinia virus infected cells after in vitro stimulation. DNA immunization with mimotope, inclusion of a T-cell epitope from the HIV-1 envelope protein in the expression cassette and co-administration with IL-12 or GM-CSF encoding plasmids activate a cellular response to the HIV-1 envelope protein.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12531355     DOI: 10.1016/s0264-410x(02)00703-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

Review 1.  Harnessing benefit from targeting tumor associated carbohydrate antigens.

Authors:  Thomas Kieber-Emmons; Behjatolah Monzavi-Karbassi; Laura F Hutchins; Angela Pennisi; Issam Makhoul
Journal:  Hum Vaccin Immunother       Date:  2017-02       Impact factor: 3.452

2.  Global gene expression profiling in interleukin-12-induced activation of CD8(+) cytotoxic T lymphocytes against mouse mammary Carcinoma.

Authors:  Shanjin Cao; Zhaoying Xiang; Xiaojing Ma
Journal:  Cell Mol Immunol       Date:  2004-10       Impact factor: 11.530

3.  Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice.

Authors:  Robert W Maitta; Kausik Datta; Andrew Lees; Shelley Sims Belouski; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

Review 4.  Bridging innate and adaptive antitumor immunity targeting glycans.

Authors:  Anastas Pashov; Bejatolah Monzavi-Karbassi; Gajendra P S Raghava; Thomas Kieber-Emmons
Journal:  J Biomed Biotechnol       Date:  2010-06-15

5.  The promise of the anti-idiotype concept.

Authors:  Thomas Kieber-Emmons; Bejatohlah Monzavi-Karbassi; Anastas Pashov; Somdutta Saha; Ramachandran Murali; Heinz Kohler
Journal:  Front Oncol       Date:  2012-12-19       Impact factor: 6.244

Review 6.  Tumor-Associated Glycans and Immune Surveillance.

Authors:  Behjatolah Monzavi-Karbassi; Anastas Pashov; Thomas Kieber-Emmons
Journal:  Vaccines (Basel)       Date:  2013-06-17

7.  Carbohydrate mimetic peptides augment carbohydrate-reactive immune responses in the absence of immune pathology.

Authors:  Leah Hennings; Cecile Artaud; Fariba Jousheghany; Behjatolah Monzavi-Karbassi; Anastas Pashov; Thomas Kieber-Emmons
Journal:  Cancers (Basel)       Date:  2011-11-11       Impact factor: 6.639

Review 8.  Carbohydrate-mimetic peptides for pan anti-tumor responses.

Authors:  Thomas Kieber-Emmons; Somdutta Saha; Anastas Pashov; Behjatolah Monzavi-Karbassi; Ramachandran Murali
Journal:  Front Immunol       Date:  2014-06-30       Impact factor: 7.561

9.  T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation-Updated Consensus and Review 2020.

Authors:  Vibha Jawa; Frances Terry; Jochem Gokemeijer; Shibani Mitra-Kaushik; Brian J Roberts; Sophie Tourdot; Anne S De Groot
Journal:  Front Immunol       Date:  2020-06-30       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.